Operations

Califf to Lead Patient-Centered Research Foundation

March 30, 2017

by David Raths Nonprofit formed by PCORnet investigators to support the network’s sustainability Robert Califf, M.D., who stepped down as commissioner of the U.S. Food and Drug Administration in January, has been named chair of a new nonprofit organization, the People-Centered Research Foundation, which has been created to sustain and expand a national network for […]

Amgen plans to shuffle and cut hundreds of jobs

March 30, 2017

By Samantha Masunaga Hundreds of Amgen employees in Thousand Oaks will relocate to other cities or change jobs, and some will be laid off, the biotech giant has said. The company sent an announcement to staff last week, saying that it notified almost 500 people about “changes to their roles” over the next year and […]

Reuters Exclusive – PPD’s private equity owners in talks to sell stakes

March 30, 2017

By Carl O’Donnell and Greg Roumeliotis The two buyout firms that own Pharmaceutical Product Development LLC (PPD) are in advanced talks to sell some of their stakes in the U.S. clinical trials firm at a price that would value the entire company at more than $9 billion (7.23 billion pounds), including debt, people familiar with […]

Worldwide Clinical Trials Selects William “Bill” Hirschman As New Head Of Global Business Development

March 30, 2017

MORRISVILLE, NC, mARCH 30, 2017 – William “Bill” Hirschman has joined the leadership team of Worldwide Clinical Trials (www.worldwide.com), one of the world’s leading, full-service contract research organizations (CROs), as Executive Vice President and head of Global Business Development. Hirschman will lead Worldwide’s growing business development organization, a large global team that includes sales, sales […]

The Pistoia Alliance Calls on the Life Sciences to Support Greater Collaboration to Overcome Technology Challenges

March 30, 2017

Machine learning, deep learning, and pre-competitive data analysis will deliver tangible benefits to patients  The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, is calling upon the industry to improve collaborative efforts to use patient data to its full effect. In a series of […]

Linguamatics and Dow Jones Partner to Accelerate Pharma Industry Research

March 29, 2017

Cambridge, UK & Boston, USA – March 28, 2017 – Market leading NLP text analytics providerLinguamatics today announced a partnership with premium news content providerDow Jones. The agreement allows pharmaceutical companies to extract key insights from Dow Jones Factiva utilizing LinguamaticsI2E text mining technology. The Linguamatics I2E platform is currently used by 18 of the […]

Heat Biologics Closes Public Offering of 5,000,000 Shares of Common Stock

March 29, 2017

DURHAM, N.C., March 28, 2017 (GLOBE NEWSWIRE) — Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced the closing of an underwritten public offering of 5,000,000 shares of common stock at a price to the public of $0.80 per share. The gross […]

Genstar Capital Announces Acquisition of Bracket

March 29, 2017

SAN FRANCISCO, March 28, 2017 /PRNewswire/ — Genstar Capital, a leading middle-market private equity firm focused on investments in targeted segments of the healthcare, financial services, software, and industrial technology industries, today announced that it has acquired Bracket, a leading scientifically-driven clinical trial technology and specialty services provider, from Parthenon Capital Partners. Bracket offers an […]

Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer

March 29, 2017

HERTFORDSHIRE, England and PITTSBURGH, March 28, 2017 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Daniel M. Gallagher as chief legal officer. He will be joining the company on April 17, 2017. Gallagher joins Mylan from Patomak Global Partners, a consulting firm providing strategic advice, compliance consulting, and litigation and regulatory […]

Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress

March 29, 2017

FREMONT, Calif., March 28, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today reported financial and operational results for the fourth quarter and year ended December 31, 2016 as well as recent corporate progress.   “Asterias has achieved substantial progress over the last year, highlighted […]

Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

March 29, 2017

SAN DIEGO, March 28, 2017 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the fourth quarter and year ended December 31, 2016.   “Last year was a year of transformational progress for Orexigen, beginning with the re-acquisition of the rights to Contrave® in the United States. Commencing early March, […]

AVEO Announces Pricing of $15.0 Million Public Offering of Common Stock

March 29, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $15 million. All of the shares in the offering are […]

NantHealth to Report 2016 Fourth-Quarter, Full-Year Financial Results and Host Conference Call on Thursday, March 30

March 29, 2017

CULVER CITY, Calif.–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2016 fourth quarter and full year on Thursday, March 30, 2017, after market close. NantHealth management will host a conference call that same day at 1:30 p.m. PT (4:30 p.m. ET) to […]

Enumeral Reports Year End 2016 Financial Results

March 29, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced its financial results for the year ended December 31, 2016. “Over the last several months we have been actively engaged in our turnaround […]

Aeterna Zentaris Announces At the Market Issuance Program

March 29, 2017

CHARLESTON, S.C.–(BUSINESS WIRE)–Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS): All dollar amounts are stated in US$ Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the “Company”) announced today that it has commenced a new “at-the-market” offering pursuant to its existing At Market Issuance (“ATM”) Sales Agreement, dated April 1, 2016, with H.C. Wainwright & Co., LLC (the “Sales Agent”), under […]

VERIFY BRAND PLATFORM 8.0 BUILDS ON LONG-STANDING SUPPORT FOR GS1 DATA STANDARDS; HELPS COMPANIES ENABLE DATA EXCHANGE WITH EPCIS 1.2

March 29, 2017

MINNEAPOLIS – March 28, 2017 – Verify Brand, a leader in serialization and traceability software for pharmaceutical and consumer product goods companies, has announced enhancements to its serialization platform. Version 8.0 of the Verify Platform includes user-friendly, real-time analytics for better business insights, as well as updates to existing functionality of the software’s GS1 EPCIS […]

INC Research Accelerates Clinical Trial Startup with goBalto Activate

March 29, 2017

SAN FRANCISCO, March 28, 2017 — goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today results from its ongoing partnership with INC Research (NASDAQ: INCR), a leading global CRO and pioneer in the implementation of goBalto’s end-to-end study startup platform to accelerate delivery of Phase I to IV clinical trials for […]

Aptose Reports Fourth Quarter and Year End 2016 Results

March 29, 2017

SAN DIEGO and TORONTO, March 28, 2017 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months and fiscal year ended December 31, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are […]

Interim Results for the six months ended 31 December 2016

March 29, 2017

29 March 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2016. Highlights (including post period end highlights) Financial highlights Revenue increased by 18% at constant currency to £34.2m (H1 2016: £29.0m)* while reported revenue increased by […]

Final Results for the year ended 31 December 2016

March 29, 2017

TURKU – FINLAND, 29 March 2017 Faron Pharmaceuticals Ltd (”Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today reports its full year audited results for the year ended 31 December 2016. The 2016 Annual Report and Accounts become available in mid-April in digital form on the Company’s website together with the invitation to the Annual […]

Emisphere Reports Fourth Quarter and Full Year 2016 Financial Results

March 29, 2017

ROSELAND, N.J., March 29, 2017 (GLOBE NEWSWIRE) — Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the fourth quarter and full fiscal year ended December 31, 2016, and provided an overview of corporate accomplishments and plans. “The last twelve months have been a pivotal time for Emisphere,” said Alan L. Rubino, President and Chief […]

Cidara Therapeutics to Host Investor Day on April 6, 2017

March 29, 2017

SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day on Thursday, April 6, 2017, from 8:30 a.m. to 11:30 a.m. EDT (5:30 a.m. to 8:30 a.m. PDT) in New York City. Jeffrey Stein, Ph.D., president and chief executive officer, […]

CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.

March 29, 2017

NEWARK, Calif., March 29, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that Harold Van Wart, Ph.D., will retire as President and Chief Executive Officer. The Board of Directors has promoted Sujal Shah, to interim President and […]

AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights

March 28, 2017

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced financial results for the quarter and year ended December 31, 2016. “The growing incidence of antibiotic-resistant bacterial infections is a major health threat that is recognized by governments and health authorities […]

European Patent Office to Grant Broad Claims on Patent Covering CRISPR-Cas9 Gene Editing Technology

March 28, 2017

DUBLIN–(BUSINESS WIRE)–ERS Genomics announced today that the European Patent Office (EPO) intends to grant Dr. Emmanuelle Charpentier, ERS Genomics’ co-founder, together with the University of California and University of Vienna, a patent with very broad claims covering the use of CRISPR-Cas9 technology for gene editing. The claims intended for grant by the EPO are directed […]

AVEO Announces Proposed Offering of Common Stock

March 28, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size […]

Key BioTime Patents Upheld by European Patent Office

March 28, 2017

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing products addressing degenerative disease, today announced the successful defense of two key patents from challenge before the European Patent Office (EPO) Opposition division. A large pharmaceutical company and an anonymous filer challenged the EPO’s previous grant of two European patents (EP2554661 […]

FEEDBACK